Systemic and SARS-CoV-2 specific Immune Disturbances in Individuals With Post–COVID Syndrome
The Journal of Infectious Diseases · 30.07.2025 · 232 (1) · 50-59
DOI: 10.1093/infdis/jiaf211 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 25.04.2025. Verfasst von Veronica Ober und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Department of Medicine IV, LMU University Hospital, LMU Munich, Munich, Germany. Hauptthemen laut MEDLINE: COVID-19, SARS-CoV-2. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: Bavarian State Ministry for Health and Care, Bavarian State Office for Health and Food Safety, German Center for Infection Research.
Abstract (Originalsprache)
Background
Post–coronavirus disease 2019 syndrome (PCS) is characterized by persistent symptoms lasting >12 weeks after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The underlying pathological mechanisms remain poorly understood.
Methods
We conducted detailed immunological analyses in 47 individuals with PCS, assessed >12 weeks after acute SARS-CoV-2 infection, and we compared them with 25 convalescent controls without symptoms. We performed immune phenotyping of T- and B-cell subsets, assessed SARS-CoV-2–specific responses using activation-induced marker (AIM) flow cytometry for T cells, and tetramer staining of spike-specific B cells. Cytokine levels in peptide-stimulated cell supernatants and plasma were quantified using a Luminex platform.
Results
Individuals with PCS exhibited reduced frequencies of AIM-positive SARS-CoV-2–specific T cells (OX40+PDL1+) and CD8 T cells (CD137+CD69+) following peptide stimulation with spike or nucleocapsid antigen, accompanied by diminished interferon γ and interleukin 2, as measured in the cell culture supernatants. In contrast, non–virus-specific T-cell populations, including memory differentiation, activation and helper cell differentiation status, did not differ between the groups. Individuals with PCS showed a significant increase in total (CD19+) and activated (CD86+HLA-DR+) B cells but not in SARS-CoV-2 spike–specific B cells (approximately 0.2% of total B cells). Plasma cytokine analysis revealed elevated markers associated with vascular damage and inflammation in those with PCS.
Conclusions
Persistent immune disturbances in individuals with PCS are characterized by reduced SARS-CoV-2–specific T-cell responses, increased B-cell activation, and altered inflammatory and vascular biomarkers. These findings provide insights into the underlying mechanisms of PCS and may contribute to biomarker discovery and therapeutic development. Trial no DRKS00030974 (registry: https://www.bfarm.de/EN/BfArM/Tasks/German-Clinical-Trials-Register/_node.html).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases, Department of Medicine IV, LMU University Hospital, LMU Munich, Munich, Germany.
- German Centre for Infection Research (DZIF), Partner Site Munich, Munich, Germany.
- Medical Faculty, The M3 Research Center, University Clinic Tübingen, Tübingen, Germany.
- Department of Medicine IV, LMU University Hospital, LMU Munich, Munich, Germany.
- Department of Internal Medicine IV, Division of Diabetology, Endocrinology and Nephrology, University Hospital, Eberhard-Karls-Universität Tübingen, Tübingen, Germany.
- COVID-19 Registry of the LMU Munich, LMU University Hospital, LMU Munich, Munich, Germany.
ORCID-Profile: Veronica Ober, Felix Völk, Julia Sbierski-Kind, Eva Grüner, Hans Stubbe, Kristina Adorjan, Johannes R Bogner, Julia Roider
Förderung
- Bavarian State Ministry for Health and Care
- Bavarian State Office for Health and Food Safety
- German Center for Infection Research
- Else Kröner-Fresenius-Stiftung
Zitieren
APA
Ober, V., Völk, F., Sbierski-Kind, J., Grüner, E., Stirner, R., Reiling, G., Feldmann, S., Ibarra, G., Seybold, U., Stubbe, H., Adorjan, K., Bogner, J. R., & Roider, J. (2025). Systemic and SARS-CoV-2 specific Immune Disturbances in Individuals With Post–COVID Syndrome. The Journal of Infectious Diseases, 232(1), 50-59. https://doi.org/10.1093/infdis/jiaf211
Vancouver
Ober V, Völk F, Sbierski-Kind J, Grüner E, Stirner R, Reiling G, et al. Systemic and SARS-CoV-2 specific Immune Disturbances in Individuals With Post–COVID Syndrome. The Journal of Infectious Diseases. 2025;232(1):50-59. doi:10.1093/infdis/jiaf211
BibTeX
@article{Ober2025,
author = {Ober, Veronica and Völk, Felix and Sbierski-Kind, Julia and Grüner, Eva and Stirner, Renate and Reiling, Gabriele and Feldmann, Svenja and Ibarra, Gerardo and Seybold, Ulrich and Stubbe, Hans and Adorjan, Kristina and Bogner, Johannes R and Roider, Julia},
title = {Systemic and SARS-CoV-2 specific Immune Disturbances in Individuals With Post–COVID Syndrome},
journal = {The Journal of Infectious Diseases},
year = {2025},
volume = {232},
number = {1},
pages = {50--59},
doi = {10.1093/infdis/jiaf211}
}
EUVIMED